Short Interest in UCB SA (OTCMKTS:UCBJF) Expands By 49.8%

UCB SA (OTCMKTS:UCBJF) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 373,700 shares, a growth of 49.8% from the April 30th total of 249,500 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 3,737.0 days. Approximately 0.2% of the company’s shares are sold short.

UCB Trading Up 2.1%

UCB stock opened at $179.39 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average price is $163.60 and its two-hundred day moving average price is $179.93. UCB has a twelve month low of $149.85 and a twelve month high of $209.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.